To assess the efficacy of long-term calcium and vitamin D treatment on bone mineral density (BMD) in HIV+ patients on combined antiretroviral therapy (cART). A retrospective, single-center cohort study. Between March 2010 and July 2012, 268 HIV+ patients were screened for vitamin D and calcium deficiency. Those with proven vitamin D or calcium deficiency received supplementation according to a predefined protocol, and were offered further evaluation of BMD by dual-energy X-ray absorptiometry (DEXA). Calcium and vitamin D status and BMD were assessed at baseline (T0) and approximately one (T1) and 4–6 years (T2) later. Percentual change in BMD of the lumbar spine and hip was compared with reported rates of change in HIV+ patients on cART without standard calcium and vitamin D treatment. The prevalence of vitamin D deficiency and calcium deficiency was 46% and 43%, respectively. Thirteen percent of patients had secondary hyperparathyroidism at baseline. DEXA performed in patients with a deficiency revealed osteopenia in 40% and osteoporosis in 8% of patients. The expected long-term change in lumbar spine and hip BMDs at T2 was −0.7%, −1.5%, and −1.5%, respectively. The measured changes were +2.3%, −0.6%, and −0.6%, respectively. The difference between measured and expected rate of change was significant for the lumbar spine (3.0%, p < .05), but not for the hip. Long-term vitamin D and calcium supplementation improves lumbar spine BMD of HIV+ patients with osteopenia or osteoporosis and with proven calcium and/or vitamin D deficiencies. Screening and treatment are recommended to become part of regular care.
Get full access to this article
View all access options for this article.
References
1.
AhmadAN, AhmadSN, AhmadN: HIV infection and bone abnormalities. Open Orthop J, 2017; 11:777.
2.
GouletJL, FultzSL, RimlandD, et al.: Do patterns of comorbidity vary by HIV status, age, and HIV severity?. Clin Infect Dis, 2007; 45:1593–1601.
3.
CrothersK, ButtAA, GibertCL, Rodriguez-BarradasMC, CrystalS, JusticeAC: Increased COPD among HIV-positive compared to HIV-negative veterans. Chest, 2006; 130:1326–1333.
4.
SudanoI, SpiekerLE, NollG, CortiR, WeberR, LüscherTF: Cardiovascular disease in HIV infection. Am Heart J, 2006; 151:1147–1155.
5.
JusticeAC: Prioritizing primary care in HIV: Comorbidity, toxicity, and demography. Top HIV Med, 2006; 14.5:159–163.
6.
HoyJ, YoungB: Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. Curr Opin HIV AIDS, 2016; 11.3:301–305.
7.
KnobelH, GuelarA, VallecilloG, NoguésX, DíezA: Osteopenia in HIV-infected patients: Is it the disease or is it the treatment?. AIDS, 2001; 15:807–808.
8.
BonjochA, FiguerasM, EstanyC, et al.: High prevalence of and progression to low bone mineral density in HIV-infected patients: A longitudinal cohort study. AIDS, 2010; 24:2827–2833.
9.
EscotaGV, MondyK, BushT, et al.: High prevalence of low bone mineral density and substantial bone loss over 4 years among HIV-infected persons in the era of modern antiretroviral therapy. AIDS Res Hum Retroviruses, 2016; 32:59–67.
10.
PaccouJ, VigetN, Legrout-GérotI, YazdanpanahY, CortetB: Bone loss in patients with HIV infection. Joint Bone Spine, 2009; 76.6:637–641.
11.
BrownTT, McComseyGA, KingMS, QaqishRB, BernsteinBM, Da SilvaBA: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr, 2009; 51:554–561.
12.
DuvivierC, KoltaS, AssoumouL, et al.: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS, 2009; 23:817–824.
13.
AssoumouL, KatlamaC, ViardJP, et al.: Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS, 2013; 27:2425–2430.
14.
BriotK, KoltaS, FlandreP, et al.: Prospective one-year bone loss in treatment-naive HIV+ men and women on single or multiple drug HIV therapies. Bone, 2011; 48:1133–1139.
15.
GallantJE, StaszewskiS, PozniakAL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA, 2004; 292:191–201.
16.
GrantPM, KitchD, McComseyGA, et al.: Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. J Infect Dis, 2016; 214:607–611.
17.
BollandMJ, WangTK, GreyA, GambleGD, ReidIR: Stable bone density in HAART-treated individuals with HIV: A meta-analysis. J Clin Endocrinol Metab, 2011; 962721–2731.
18.
StellbrinkHJ, OrkinC, ArribasJR, et al.: Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis, 2010; 51:963–972.
19.
McComseyGA, KitchD, DaarES, et al.: Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis, 2011; 203; 1791–1801.
20.
HuangJS, HughesMD, RiddlerSA, Haubrich RHAI, DS Clinical Trials Group A5142 Study Team: Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials, 2013; 14:224–234.
21.
BrownTT, RossAC, StorerN, LabbatoD, McComseyGA: Bone turnover, OPG/RANKL, and inflammation with antiretroviral initiation: Comparison of tenofovir-vs. non-tenofovir regimens. Antivir Ther, 2011; 16:1063.
22.
KinaiE, NishijimaT, MizushimaD, et al.: Long-term use of protease inhibitors is associated with bone mineral density loss. AIDS Res Hum Retroviruses, 2014; 30:553–559.
23.
TebasP, PowderlyWG, ClaxtonS, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (London, England), 2000; 14:F63.
24.
ZuccottiG, ViganòA, GabianoC, et al.: Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone, 2010; 46:1633–1638.
25.
BedimoR, MaaloufNM, ZhangS, DrechslerH, TebasP: Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS, 2010; 26:825–831.
26.
HilemanCO, OvertonET, McComseyGA: Vitamin D and bone loss in HIV. Curr Opin HIV AIDS, 2016; 11:277.
27.
RizzoliR, BoonenS, BrandiML, BurletN, DelmasP, ReginsterJY: The role of calcium and vitamin D in the management of osteoporosis. Bone, 2008; 42:246–249.
28.
PisoRJ, RothenM, RothenJP, StahlM, FuxC: Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients. BMC Infect Dis, 2013; 13:577.
29.
McComseyGA, KendallMA, TebasP, et al.: Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS, 2007; 21:2473–2482.
30.
MondyK, PowderlyWG, ClaxtonSA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. JAIDS J Acquir Immune Defic Syndr, 2005; 38:426–431.
31.
Battegay et al.: EACS Guidelines, version 9.1, 2018. https://aidsinfo.nih.gov/guidelines/search?q=osteoporosis&c=guidelines&htmldocId=1&startAt=0 accessed February2019.
32.
Battegay et al.: EACS Guidelines, version 9.1, section Prevention and Management of Comorbidities in HIV-positive person 2018. https://aidsinfo.nih.gov/guidelines/search?q=osteoporosis&c=guidelineshtmldocId=1&startAt=0 accessed February2019.
33.
AbergJA, GallantJE, GhanemKG, EmmanuelP, ZingmanBS, HorbergMA: Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis, 2013; 58:e1–e34.
34.
OvertonET, ChanES, BrownTT, et al.: High-dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation: A prospective, randomized placebo-controlled trial for bone health in HIV-infected individuals. Ann Intern Med, 2015; 162:815–824.
35.
Hossein-nezhadA, HolickMF: Vitamin D for health: A global perspective. Mayo Clin Proc, 2013; 88:720–755.
36.
van GroningenL, OpdenoordtS, van SorgeA, TeltingD, GiesenA, de BoerH: Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol, 2010; 162:805–811.
37.
Bischoff-FerrariH. Vitamin D: What is an adequate vitamin D level and how much supplementation is necessary?. Best Pract Res Clin Rheumatol, 2009; 23:789–795.
38.
TietzNW: Text Book of Clinical Chemistry. WB Saunders, Philadelphia, 1986.
39.
WHO Scientific Group on the Prevention and Management of Osteoporosis 2003 Prevention and Management of Osteoporosis: Report of a WHO Scientific Group. World Health Organization, Geneva.
40.
CatalanoA, ChilàD, BelloneF, et al.: Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?. J Clin Transl Endocrinol, 2018; 13:9–13.
41.
BenguellaL, ArbaultA, FillionA, et al.: Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients. Med Mal Infect, 2018; 48:449–456.
42.
NoeS, HeldweinS, PascucchiR, et al.: Cholecalciferol 20 000 IU Once Weekly in HIV-Positive patients with low vitamin D levels: Result from a Cohort Study. J Int Assoc Provid AIDS Care, 2017; 16:315–320.
43.
Lerma-ChippirrazE, Güerri-FernándezR, Villar GarcíaJ, et al.: Validation protocol of vitamin D supplementation in patients with HIV-Infection. AIDS Res Treat, 2016; 2016:5120831.
44.
VerhaarJAN, MourikJBAV, eds: Orthopedie. Bohn Stafleu van Loghum, 2009.
45.
ClarkeB: Normal bone anatomy and physiology. Clin J Am Soc Nephrol, 2008; 3 (Suppl 3):S131–S139.
46.
CherneyDD, LaymonMS, McNittA, YulyS: A study on the influence of calcified intervertebral disk and aorta in determining bone mineral density. J Clin Densitom, 2002; 5:193–198.
47.
DrinkaPJ, DeSmetAA, BauwensSF, RogotA: The effect of overlying calcification on lumbar bone densitometry. Calcif Tissue Int, 1992; 50:507–510.
48.
ChenMA, KawakuboM, CollettiPM, et al.: Effect of age on aortic atherosclerosis. J Geriatr Cardiol, 2013:10:135.
49.
DeJesusE, HaasB, Segal-MarerS, et al.: Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate-to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retroviruses, 2018; 34.4:337–342.
50.
MoranCA, WeitzmannMN, OfotokunI: The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS, 2016; 11:333–342.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
